G12.21

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rapidly progressive, fatal neurodegenerative disease that primarily affects motor neurons in the cerebral cortex, brainstem, and spinal cord. The condition is characterized by the simultaneous degeneration of upper motor neurons (UMN) and lower motor neurons (LMN). As motor neurons degenerate, they cease sending impulses to muscle fibers, leading to muscle weakness, atrophy, and fasciculations. ALS is typically classified as either sporadic (occurring without a clear family history in approximately 90-95% of cases) or familial (inherited in approximately 5-10% of cases). The disease progression eventually leads to the loss of voluntary muscle control, including the muscles necessary for speech, swallowing, and respiration, typically resulting in respiratory failure within 3 to 5 years of symptom onset, although some individuals may survive for a decade or longer.

Clinical Symptoms

Progressive muscle weakness, typically starting in the extremities (limb-onset) or bulbar muscles (bulbar-onset)
Muscle atrophy and wasting
Fasciculations (visible muscle twitching), especially in the tongue and limbs
Muscle cramps and painful spasms
Spasticity and hyperreflexia (signs of upper motor neuron involvement)
Dysarthria (difficulty speaking or slurring of words)
Dysphagia (difficulty swallowing and frequent choking)
Shortness of breath and decreased respiratory drive
Pseudobulbar affect (uncontrollable laughter or crying)
Weight loss due to muscle mass loss and metabolic changes
Drop foot or difficulty walking
Weakness in the hands leading to clumsiness or difficulty with fine motor tasks
Frontotemporal cognitive impairment (in a subset of patients)

Common Causes

Sporadic etiology (unknown cause in the majority of cases)
Genetic mutations, most commonly in the C9orf72, SOD1, TARDBP (TDP-43), and FUS genes
Glutamate excitotoxicity (overstimulation of neurons leading to cell death)
Protein misfolding and aggregation within motor neurons
Oxidative stress and mitochondrial dysfunction
Neuroinflammation and immune system activation
Disruption of axonal transport mechanisms
Advanced age (typically appearing between 40 and 70 years)
Male sex (slightly higher prevalence in men compared to women)
Environmental triggers, though specific factors remain under investigation

Documentation & Coding Tips

Distinguish between Upper Motor Neuron and Lower Motor Neuron signs across body segments.

Example: Neurological examination reveals hyperreflexia and Babinski sign (UMN) in the bilateral lower extremities alongside significant muscle atrophy and visible fasciculations (LMN) in the tongue and deltoids. This combination of UMN and LMN signs in multiple regions supports the definitive diagnosis of Amyotrophic lateral sclerosis, which is a chronic, progressive condition under HCC 6.

Billing Focus: Specificity of clinical findings across bulbar, cervical, and lumbosacral regions to justify G12.21.

Explicitly document bulbar involvement including speech and swallowing deficits.

Example: Patient presents with progressive dysarthria and oropharyngeal dysphagia. Examination shows tongue fasciculations and slow palatal movement. These bulbar symptoms are primary manifestations of the patient's G12.21 diagnosis and necessitate referral for speech-language pathology and swallow evaluation.

Billing Focus: Documentation of secondary symptoms like dysphagia or dysarthria that may require additional ICD-10 codes for complete capture.

Record specific respiratory assessment results to monitor disease progression.

Example: Spirometry today demonstrates a Forced Vital Capacity (FVC) of 45 percent predicted, indicating severe respiratory insufficiency secondary to Amyotrophic lateral sclerosis. Patient is currently utilizing nocturnal BiPAP for support. This chronic respiratory failure is documented alongside G12.21.

Billing Focus: Supports the use of J96.10 (Chronic respiratory failure) as a co-morbidity.

Detail nutritional status and the presence of enteral access devices.

Example: Due to progressive dysphagia and a 15-pound weight loss (BMI 17.5), a percutaneous endoscopic gastrostomy (PEG) tube was placed on 05/12/2025. Patient is now meeting 100 percent of nutritional needs via enteral formula. Diagnosis: G12.21 with associated severe protein-calorie malnutrition.

Billing Focus: Linkage between ALS, nutritional status (E43), and the presence of a gastrostomy status (Z93.1).

Document the use of multidisciplinary care and functional scales like ALSFRS-R.

Example: Patient seen in multidisciplinary ALS clinic. ALS Functional Rating Scale-Revised (ALSFRS-R) score is 28/48, reflecting moderate functional decline in fine motor tasks and respiratory function. Current medications include Riluzole 50mg BID and Edaravone IV infusions.

Billing Focus: Provides evidence of high-level medical decision making and complexity for E/M leveling.

Relevant CPT Codes

99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making or the physician or other qualified health care professional spends 40-54 minutes of total time on the date of the encounter.
ALS is a progressive, life-threatening condition requiring complex management of multiple organ systems (neurological, respiratory, nutritional).
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making or the physician or other qualified health care professional spends 30-39 minutes of total time on the date of the encounter.
Used for routine follow-ups where the condition is stable but still requires management of chronic medications.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a low level of medical decision making or the physician or other qualified health care professional spends 20-29 minutes of total time on the date of the encounter.
Used for highly focused or single-issue visits such as a simple medication refill or post-procedure check.
95886 - Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles checked, with related paraspinal areas, when performed
Essential diagnostic procedure to identify the lower motor neuron involvement required for an ALS diagnosis.
95913 - Nerve conduction studies; 13 or more studies
Used in conjunction with EMG to rule out other peripheral nerve disorders like multifocal motor neuropathy.
94010 - Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
Required to monitor respiratory muscle strength and progress in ALS patients.
43246 - Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube
Standard procedure for ALS patients with significant dysphagia and weight loss to maintain nutrition.
64616 - Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral
Often used off-label for the management of sialorrhea (excessive drooling) in ALS patients.
92523 - Evaluation of speech sound production; with evaluation of language comprehension and expression
Critical for assessing bulbar onset patients for communication devices and swallow safety.
97802 - Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes
Crucial for preventing the rapid weight loss and malnutrition associated with poor ALS outcomes.